AviadoBio Completes Second Cohort in Phase 1/2 Trial for Frontotemporal Dementia Gene Therapy
• AviadoBio has completed dosing the second cohort in its ASPIRE-FTD clinical trial evaluating AVB-101, a gene therapy for frontotemporal dementia with GRN mutations, with plans to initiate a third cohort in Q3 2025.
• The company reported no clinically significant safety findings in the first cohort through 52 weeks of follow-up, with no immunosuppression required, marking an important milestone in the development pathway.
• AVB-101 uses a novel delivery approach, administering the gene therapy directly to the thalamus via neurosurgical procedure to bypass the blood-brain barrier and target affected brain regions more precisely.
© Copyright 2025. All Rights Reserved by MedPath